The results revealed that administration of J3 at different doses for 12 weeks decreased the levels of T-HTT and DARPP-32 in HdhQ140/Q140, indicating that HD changes could be ameliorated by J3 (Fig. 6A, B, Additional file 6: S6A-B). This evidence concerns the gene PPP1R1B and Huntington disease.